VANCOUVER and SAN DIEGO, Nov. 15 /CNW/ - MIGENIX Inc. (TSX: MGI; OTC:
MGIFF), a clinical-stage developer of drugs for infectious and degenerative
diseases, has issued its 19th CEO Message from Jim DeMesa, MD, President &
CEO. Today's CEO Message provides a review of the celgosivir (MX-3253) Phase
II results in HCV non-responder patients announced November 6, 2006, and the
Company's key milestones for 2007 including:
